Arovella Therapeutics (ASX:ALA) Operating Cash Flow per Share

: A$-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Arovella Therapeutics's operating cash flow per share for the six months ended in Dec. 2023 was A$-0.00. Arovella Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 19.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 23.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Arovella Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

ASX:ALA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -31 Med: 19.1 Max: 37.7
Current: 19.1

During the past 13 years, Arovella Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 37.70% per year. The lowest was -31.00% per year. And the median was 19.10% per year.

ASX:ALA's 3-Year OCF Growth Rate is ranked better than
68.1% of 1235 companies
in the Biotechnology industry
Industry Median: 3.2 vs ASX:ALA: 19.10

Arovella Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Arovella Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.02

-0.01

Arovella Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.01	-0.01	-	-0.01	-

Competitive Comparison

For the Biotechnology subindustry, Arovella Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Price-to-Operating-Cash-Flow falls into.

Arovella Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Arovella Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )	=	Cash Flow from Operations (A: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2023 )
	=	-6.398	/	711.483
	=	-0.01

Arovella Therapeutics's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-2.64	/	900.515
	=	-0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

Arovella Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics (ASX:ALA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

E4NA:Germany

Address

62 Lygon Street, Level 3, Carlton, WA, AUS, 3053

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (ASX:ALA) Headlines

No Headlines